JPWO2019156907A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019156907A5 JPWO2019156907A5 JP2020542665A JP2020542665A JPWO2019156907A5 JP WO2019156907 A5 JPWO2019156907 A5 JP WO2019156907A5 JP 2020542665 A JP2020542665 A JP 2020542665A JP 2020542665 A JP2020542665 A JP 2020542665A JP WO2019156907 A5 JPWO2019156907 A5 JP WO2019156907A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- proline
- powder
- crystal according
- ray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 claims description 72
- 229960002429 proline Drugs 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 32
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 24
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 21
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 18
- 229930182821 L-proline Natural products 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 12
- 230000005855 radiation Effects 0.000 claims description 12
- 238000001757 thermogravimetry curve Methods 0.000 claims description 12
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 8
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- -1 3'-fluoro- [1,1'-biphenyl] -2-yl Chemical group 0.000 claims description 7
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 229910017488 Cu K Inorganic materials 0.000 claims description 4
- 229910017541 Cu-K Inorganic materials 0.000 claims description 4
- 229930182820 D-proline Natural products 0.000 claims description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002411 thermogravimetry Methods 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 125000004326 2H-pyran-2-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])(*)O1 0.000 claims description 2
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims description 2
- 125000000180 D-prolyl group Chemical group N1[C@@H](C(=O)*)CCC1 0.000 claims description 2
- 101710113864 Heat shock protein 90 Proteins 0.000 claims description 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 2
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 2
- 230000020169 heat generation Effects 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- PDBWOHBMJQOBHL-WBADGQHESA-N n-[2-[4-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-(3-fluorophenyl)phenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)[C@@H]1OC1=CC=C(CCNC(C)=O)C(C=2C=C(F)C=CC=2)=C1 PDBWOHBMJQOBHL-WBADGQHESA-N 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023173340A JP2024001167A (ja) | 2018-02-07 | 2023-10-05 | ノボビオシン類似体とプロリンとの共結晶形態 |
| JP2025178611A JP2026012851A (ja) | 2018-02-07 | 2025-10-23 | ノボビオシン類似体とプロリンとの共結晶形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627570P | 2018-02-07 | 2018-02-07 | |
| US62/627,570 | 2018-02-07 | ||
| PCT/US2019/016304 WO2019156907A1 (en) | 2018-02-07 | 2019-02-01 | Co-crystal forms of a novobiocin analog and proline |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023173340A Division JP2024001167A (ja) | 2018-02-07 | 2023-10-05 | ノボビオシン類似体とプロリンとの共結晶形態 |
| JP2025178611A Division JP2026012851A (ja) | 2018-02-07 | 2025-10-23 | ノボビオシン類似体とプロリンとの共結晶形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512910A JP2021512910A (ja) | 2021-05-20 |
| JPWO2019156907A5 true JPWO2019156907A5 (https=) | 2022-02-04 |
| JP2021512910A5 JP2021512910A5 (https=) | 2022-02-04 |
Family
ID=65444361
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542665A Pending JP2021512910A (ja) | 2018-02-07 | 2019-02-01 | ノボビオシン類似体とプロリンとの共結晶形態 |
| JP2023173340A Withdrawn JP2024001167A (ja) | 2018-02-07 | 2023-10-05 | ノボビオシン類似体とプロリンとの共結晶形態 |
| JP2025178611A Pending JP2026012851A (ja) | 2018-02-07 | 2025-10-23 | ノボビオシン類似体とプロリンとの共結晶形態 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023173340A Withdrawn JP2024001167A (ja) | 2018-02-07 | 2023-10-05 | ノボビオシン類似体とプロリンとの共結晶形態 |
| JP2025178611A Pending JP2026012851A (ja) | 2018-02-07 | 2025-10-23 | ノボビオシン類似体とプロリンとの共結晶形態 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10717755B2 (https=) |
| EP (1) | EP3749675B1 (https=) |
| JP (3) | JP2021512910A (https=) |
| KR (2) | KR20240155354A (https=) |
| CN (2) | CN112020506B (https=) |
| AR (1) | AR114245A1 (https=) |
| AU (3) | AU2019217821B2 (https=) |
| BR (1) | BR112020016205A2 (https=) |
| CA (2) | CA3226385A1 (https=) |
| CL (2) | CL2020002051A1 (https=) |
| CO (1) | CO2020009761A2 (https=) |
| EA (1) | EA202091885A1 (https=) |
| IL (2) | IL276583B2 (https=) |
| MX (2) | MX2020008326A (https=) |
| MY (1) | MY209803A (https=) |
| PE (1) | PE20211446A1 (https=) |
| SG (1) | SG11202007530XA (https=) |
| TW (2) | TWI797249B (https=) |
| WO (1) | WO2019156907A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3749675B1 (en) | 2018-02-07 | 2025-12-31 | Reata Pharmaceuticals, Inc. | CO-CRISTALLIN FORMS OF A NOVOBIOCIN AND PROLINE ANALOGUE |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| CN115181146B (zh) * | 2021-04-02 | 2024-06-04 | 浙江普洛家园药业有限公司 | 一种新生霉素的提取工艺 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029369B2 (en) * | 2010-09-23 | 2015-05-12 | Nuformix Limited | Aprepitant L-proline composition and cocrystal |
| TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| CA2892832C (en) * | 2011-11-25 | 2020-04-14 | Nuformix Technologies Limited | Aprepitant l-proline solvates - compositions and cocrystals |
| EP2602249B1 (en) * | 2011-12-06 | 2015-08-12 | F.I.S. Fabbrica Italiana Sintetici S.p.A. | Synthesis of rosuvastatin by means of co-crystals |
| SMT201900660T1 (it) * | 2012-02-09 | 2020-01-14 | Univ Kansas | Inibitori c-terminali di hsp90 |
| EP2890704B1 (en) * | 2012-08-31 | 2018-02-28 | Novartis AG | 2'-ethynyl nucleoside derivatives for treatment of viral infections |
| TW201512201A (zh) * | 2013-03-14 | 2015-04-01 | Forum Pharmaceuticals Inc | 化合物的多晶型及鹽類 |
| MX388516B (es) * | 2014-06-24 | 2025-03-20 | Univ Kansas | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70. |
| KR20170060035A (ko) * | 2014-09-30 | 2017-05-31 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 나트륨 글루코스 공동운반체 2 억제제의 ｌ- 프롤린 화합물, 및 ｌ- 프롤린 화합물의 모노하이드레이트 및 결정 |
| EP3749675B1 (en) | 2018-02-07 | 2025-12-31 | Reata Pharmaceuticals, Inc. | CO-CRISTALLIN FORMS OF A NOVOBIOCIN AND PROLINE ANALOGUE |
-
2019
- 2019-02-01 EP EP19705879.5A patent/EP3749675B1/en active Active
- 2019-02-01 MY MYPI2020004057A patent/MY209803A/en unknown
- 2019-02-01 MX MX2020008326A patent/MX2020008326A/es unknown
- 2019-02-01 US US16/265,256 patent/US10717755B2/en active Active
- 2019-02-01 AU AU2019217821A patent/AU2019217821B2/en active Active
- 2019-02-01 BR BR112020016205-1A patent/BR112020016205A2/pt unknown
- 2019-02-01 CN CN201980011980.6A patent/CN112020506B/zh active Active
- 2019-02-01 JP JP2020542665A patent/JP2021512910A/ja active Pending
- 2019-02-01 CA CA3226385A patent/CA3226385A1/en active Pending
- 2019-02-01 TW TW108104336A patent/TWI797249B/zh active
- 2019-02-01 IL IL276583A patent/IL276583B2/en unknown
- 2019-02-01 PE PE2020001199A patent/PE20211446A1/es unknown
- 2019-02-01 CA CA3090646A patent/CA3090646C/en active Active
- 2019-02-01 CN CN202410935084.1A patent/CN118894894A/zh active Pending
- 2019-02-01 IL IL315865A patent/IL315865A/en unknown
- 2019-02-01 WO PCT/US2019/016304 patent/WO2019156907A1/en not_active Ceased
- 2019-02-01 SG SG11202007530XA patent/SG11202007530XA/en unknown
- 2019-02-01 KR KR1020247033920A patent/KR20240155354A/ko not_active Ceased
- 2019-02-01 EA EA202091885A patent/EA202091885A1/ru unknown
- 2019-02-01 KR KR1020207025571A patent/KR102718111B1/ko active Active
- 2019-02-01 TW TW112106332A patent/TWI868593B/zh active
- 2019-02-05 AR ARP190100277A patent/AR114245A1/es unknown
-
2020
- 2020-06-05 US US16/894,461 patent/US11401294B2/en active Active
- 2020-08-06 MX MX2022012856A patent/MX2022012856A/es unknown
- 2020-08-06 CO CONC2020/0009761A patent/CO2020009761A2/es unknown
- 2020-08-07 CL CL2020002051A patent/CL2020002051A1/es unknown
-
2022
- 2022-12-05 AU AU2022283638A patent/AU2022283638B2/en active Active
- 2022-12-27 CL CL2022003784A patent/CL2022003784A1/es unknown
-
2023
- 2023-02-13 US US18/168,495 patent/US20240043465A1/en not_active Abandoned
- 2023-10-05 JP JP2023173340A patent/JP2024001167A/ja not_active Withdrawn
-
2024
- 2024-10-25 AU AU2024227646A patent/AU2024227646A1/en active Pending
-
2025
- 2025-10-23 JP JP2025178611A patent/JP2026012851A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI839461B (zh) | Il-17a調節物及其用途 | |
| US12083118B2 (en) | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same | |
| CN102311401B (zh) | Cetp抑制剂 | |
| CA2864222C (en) | Cycloalkane derivative | |
| EP3022202B1 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| EP2928885B1 (en) | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases | |
| KR101771755B1 (ko) | 선택적 헤테로시클릭 스핑고신 1 포스페이트 수용체 조절자 | |
| JP2002526442A (ja) | プロスタグランジンｅ２アンタゴニストの新規用途 | |
| TW200848036A (en) | Novel oxycarbonyl compound | |
| CA2543533A1 (en) | 2-cyanopyrrolidinecarboxamide compound | |
| CN112424194A (zh) | 免疫调节剂及其组合物和制备方法 | |
| EP4323062B1 (en) | Heteroaryl aminopropanol derivatives as inhibitors of lta4h | |
| JP2008539218A (ja) | 新規のヒスタミンｈ３−受容体リガンドおよびそれらの治療的応用 | |
| JP2021512910A5 (https=) | ||
| JPWO2019156907A5 (https=) | ||
| WO2025103442A1 (zh) | 一种取代的2-(吡咯烷-3-基)乙酸的衍生物及其制备方法和用途 | |
| WO2006027684A1 (en) | Therapeutic diphenyl ether ligands | |
| JP6748123B2 (ja) | サクビトリルカルシウム塩 | |
| US7335673B2 (en) | 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage | |
| JPWO2020051153A5 (https=) | ||
| CN1980904A (zh) | Cetp抑制剂 | |
| CN102190656A (zh) | 含有五元杂环的噁唑烷酮抗菌素 | |
| JP7064527B2 (ja) | サクビトリルカルシウム塩 | |
| JPWO2020038983A5 (https=) | ||
| JPWO2022241278A5 (https=) |